Neuromodulatory Effects of Arecoline on Anxiety-like Behavior in Mice Exposed to Chronic Unpredictable Mild Stress.
📄 Abstract
Chronic stress disrupts neuroendocrine regulation, neurotransmitter balance, and neuronal redox homeostasis, thereby contributing to the development of anxiety-related neuropathology. Arecoline, the predominant alkaloid of
Confidence:
0.11
· 5 полей извлечено
Идентификация (6 полей)
Механизм действия (21 полей)
Mechanism
—
0.00
Mutations (obesity/lean)
—
0.00
Activity (obesity)
—
0.00
Activity temporal
—
0.00
Energy balance
—
0.00
Appetite
—
0.00
Fat metabolism
—
0.00
Lipolysis
—
0.00
Thermogenesis
—
0.00
Muscle metabolism
—
0.00
Inflammation
—
0.00
Glucose metabolism
—
0.00
AA metabolism
—
0.00
Hormonal pathways
—
0.00
Cell death
—
0.00
Adipocyte fibrosis
—
0.00
Upstream (biochem)
—
0.00
Upstream (physiol)
—
0.00
Downstream (biochem)
—
0.00
Downstream (physiol)
—
0.00
PTMs
—
0.00
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
—
0.00
In vivo
Arecoline effects on anxiety-like behavior in mice exposed to chronic unpredictable mild stress; Quercetin effects on anxiety- and depression-like behaviors in female C57BL/6 mice fed dietary advanced glycation end products; Light treatment effects on chronic restraint stress vulnerability in adult mice with adolescent social isolation stress; Schisandrol A effects on anxiety and cognitive function in mice subjected to chronic unpredictable mild stress
0.90
In silico
—
0.00
Genetic association
—
0.00
Ex vivo
—
0.00
Animal model
Mice (C57BL/6, unspecified strains)
0.90
Diet/model
Chronic unpredictable mild stress; Dietary advanced glycation end products; Chronic restraint stress with adolescent social isolation stress
0.90
Клиника (11 полей)
Drug
Arecoline
0.95
Indication
Anxiety-related neuropathology
0.90
Patient subgroups
—
0.00
Safety concerns
—
0.00
Off-target
—
0.00
Trial stage
—
0.00
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
—
0.00
Approved
—
0.00